Lyrica News and Research

RSS

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes.

28 Mar 2026

Experimental drug targets early toxic amyloid to slow Alzheimer’s disease

An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for Alzheimer's disease.

18 Dec 2025

Common nerve pain drugs may set off prescribing cascades in older patients

Clinicians may fail to recognize common side effects of drugs like gabapentin - which are frequently prescribed for nerve pain - leading them to prescribe unnecessary medications that cause yet more side effects.

2 Dec 2025

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves neuron health in animal models of Alzheimer's disease, according to a new Northwestern University study.

8 Apr 2025

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as covid-19 continues to infect tens of thousands of people and kill hundreds each day.

5 Jul 2022

Existing drug may reduce damage after spinal cord injury, research shows

Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord.

20 May 2022

Northwestern scientists receive $3.1 million grant to investigate drug therapies for ALS

Two Northwestern University scientists have received a $3.1 million grant from the National Institute on Aging to collaborate and investigate drug therapies for amyotrophic lateral sclerosis.

18 Aug 2019

FDA grants approval for generic versions of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury.

22 Jul 2019

Some clinical trials may promote use of ineffective and costly treatments, researchers say

A new paper published by McGill University researchers in JAMA Internal Medicine suggests that some clinical trials may promote the use of ineffective and costly treatments. That's the opposite of what clinical trials are aimed at, namely preventing ineffective and costly treatments from being taken up by physicians and patients.

27 Nov 2018

Researchers develop electroencephalography-based test to objectively measure pain

If you've ever visited the emergency department with appendicitis, or you're one of the 100 million U.S. adults who suffer from chronic pain, you're familiar with a row of numbered faces, with expressions from smiling to grimacing, used to indicate pain levels.

6 Nov 2018

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

A new study out today in the Journal of Neurology finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury.

25 Sep 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

17 May 2018

New molecule-building method may have great impact on pharmaceutical industry

Scientists at The Scripps Research Institute (TSRI) have devised a new molecule-building method that is likely to have a major impact on the pharmaceutical industry and many other chemistry-based enterprises.

22 Apr 2016

American Pain Society releases new post-surgical pain management guideline

The American Pain Society has released a new evidence-based clinical practice guideline, appearing in The Journal of Pain, with 32 recommendations to help clinicians achieve optimal pain management following surgery. According to numerous studies, the majority of surgical patients receive inadequate pain relief, which can heighten the risk for prolonged post-surgical pain, mood disorders and physical impairment.

18 Feb 2016

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further company clinical trials and FDA applications.

31 Dec 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

3 Apr 2014

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

Impax Laboratories, Inc. today reported fourth quarter and full year ended December 31, 2013 results.

21 Feb 2014

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

A report in the Feb. 13 New England Journal of Medicine confirms previous studies suggesting that long-term treatment with the type of drugs commonly prescribed to treat restless leg syndrome (RLS) can cause a serious worsening of the condition in some patients.

14 Feb 2014